Abstract
Human respiratory tract infections caused by gramnegative diplococci continue to remain significant issues in health care. Although not addressed as frequently as the classical diplococcal pneumonia, the gram-positive Streptococcus pneumoniae (the pneumococcus), infections due to Neisseria meningitidis (the meningococcus), and Moraxella catarrhalis (formerly called both Neisseria catarrhalis and Branhamella catarrhalis) are addressed here including their microbiology, respiratory tract manifestations, antimicrobial treatment, and potential prevention with immunization.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Holms ML, Davison WC: Meningococcal pneumonia: the occurrence of postinfluenzal pneumonia in which diplococcus intracellularis meningitis was isolated. Bull John Hopkins Hosp 1919, 30:324–329.
Banks JS: Meningococcosis: a protean disease. Lancet 1948, 1:635–640.
Putsch RW, Hamilton JD, Wolinsky E: Neisseria meningitidis, a respiratory pathogen. J Infect Dis 1970, 121:48–54.
Koppes GM, Ellenbogen C, Gebhart RJ: Group Y meningococcal disease in United States Air Force recruits. Am J Med 1977, 62:661–666.
Irwin RS, Woelk WK, Coudon WL: Primary meningococcal pneumonia. Ann Intern Med 1975, 82:493–498.
Darnell JC, Brandt MJ: Primary meningococcal pneumonia: a report of three cases. J Indiana State Med Assoc 1981, 74:794–798.
Holbein BE: Enhancement of Neisseria meningitidis infection in mice by addition of iron bound to transferrin. Infect Immun 1981, 34:120–125.
West WF, Sparling PF: The response of Neisseria gonorrhea to iron limitation: Alterations in expression of membrane proteins without apparent siderophore production. Infect Immun 1985, 47:388–394.
Dyer D, West EP, Sparling PF: Effects of seven carrier proteins on the growth of pathogenic Neisseria with heme-bound iron. Infect Immun 1987, 55:2171–2175.
Rosenstein NE, Perkins BA, Stephens DS, et al.: Meningococcal disease. N Engl J Med 2001, 344:1378–1388. An excellent review on illness due to this pathogen, and well referenced.
Kahler CM, Stephens DS: Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit Rev Microbiol 1998, 24:281–334.
Rudel T, Boxberger HJ, Meyer TF: Pilus biogenesis and epithelial cell adherence of Neisseria gonorrhea pilC double knock-out mutants. Mol Microbiol 1995, 17:1057–1071.
Virji M, Makepeace K, Peak I, et al.: Functional implication of the expression of PilC proteins in meningococci. Mol Microbiol 1995, 16:1087–1097.
Merz AJ, So M: Attachment of piliated, Opa- and Opc-gonococci and meningococci to epithelial cells elicits cortical actin rearrangements and clustering of tyrosine-phosphorylated proteins. Infect Immun 1997, 65:4341–4349.
Virji M, Makepeace K, Ferguson DJ, et al.: Meningococcal Opa and Opc proteins: Their role in colonization and invasion of human epithelial and endothelial cells. Mol Microbiol 1993, 10:499–510.
de Vries FP, Cole R, Dankert J, et al.: Neisseria meningitidis producing the Opc adhesin binds epithelial cell proteoglycan receptors. Mol Microbiol 1998, 27:1203–1212.
Stephens DS, McGee ZA: Attachment of Neisseria meningitidis to human mucosal surfaces: influence of pili and type of receptor cell. J Infect Dis 1981, 143:525–532.
Hammerschmidt S, Hilse R, van Putten JPM, et al.: Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBOJ 1996, 15:192–198.
Rose HD, Lenz IE, Sheth NK: Meningococcal pneumonia: A source of nosocomial infection. Arch Intern Med 1981, 141:575–577.
Steere A, Baltimore R, Bruce D, et al.: Nosocomial transmission of group Y Neisseria meningitidis in cancer patients. Morbid Mortal Week Rep MMWR 1978, 27:147–153.
Cohen MS, Steere AC, Baltimore R, et al.: Possible nosocomial transmission of group Y Neisseria meningitidis among oncology patients. Ann Intern Med 1979, 91:7–12.
Goldschneider I, Gotschlich EC, Artenstein MS: Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969, 129:1327–1348.
Public Health Laboratory Service: Guidelines for public health management of meningococcal disease in the UK. Commun Dis Public Health 2002, 5:187–204. An excellent recent review on the control of meningococcal disease.
Stephens DS, Hajjeh RA, Baughman WS, et al.: Sporadic meningococcal disease in adults: Results of a 5-year population-based study. Ann Intern Med 1995, 123:937–940.
Weinberg AN: Unusual bacterial pneumonias including those caused by N. meningitidis, Pseudomonas pseudomallei, Bacillus anthracis, Brucella species, Pasteurella multocida, Yersinia pestis (plague), and Francisella tularensis. In Respiratory Infections: Diagnosis and Management. Edited by Pennington JE. New York: Raven Press; 1983:299–315.
Fletcher W: Meningococcus bronchopneumonia in influenza. Lancet 1919, 1:104–106.
Young LS, LaForce FM, Head JJ, et al.: A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med 1972, 287:5–9.
Winstead JM, McKinsey DS, Tasker S, et al.: Meningococcal pneumonia: characterization and review of cases seen over the past 25 years. Clin Infect Dis 2000, 30:87–94. A good review on the topic of meningococcal pneumonia.
Centers for Disease Control and Prevention: Laboratorybased surveillance for meningococcal disease in selected areas. United States 1989–1991. Morbid Mortal Week Rep MMWR 1993, 42:21–23.
Hanson MF, Lawson A: Isolation of a group Y meningococcus from a patient with pneumonia. J Infect 1985, 10:76–79.
Yee NM, Katz M, Neu HC: Meningitis, pneumonitis and arthritis caused by Neisseria menigitidis group Y. JAMA 1975, 232:1354–1355.
Smilack JD: Group Y meningococcal disease: Twelve cases of an army training center. Ann Intern Med 1974, 81:740–745.
Woods CR, Smith AL, Wasilauskas BL, et al.: Invasive disease caused by Neisseria meningitidis relatively resistant to penicillin in North Carolina. J Infect Dis 1994, 170:453–456.
Saez-Nieto JA, Lujan R, Berron S, et al.: Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: A 5-year history (1985-1989). Clin Infect Dis 1992, 14:394–402.
Garner JS: Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996, 17:53–80.
Centers for Disease Control and Prevention: Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Week Rep MMWR 2000, 49(RR-7):1–10. The latest Advisory Committeee on Immunization Practices/ Centers for Disease Control output on the prevention and control of meningococcal disease.
Ghon A, Pfeiffer H: Der Micrococcus catarrhalis (R. Pfeiffer) als Krankheitserreger. Z Klin Med 1902, 44:263–281.
Enright MC, Mckenzie H: Moraxella (Branhamella) catarrhalis-clinical and molecular aspects of a rediscovered pathogen. J Med Microbiol 1997, 46:360–371.
Catlin BW: Transfer of the organism named Neisseria catarrhalis to Branhamella genus. Int J Syst Bacteriol 1970, 20:155–159.
Murphy TF: Moraxella (Branhamella) catarrhalis and other gram-negative cocci. In Mandell, Bennett and Douglas’ Principles and Practice of Infectious Diseases, edn 5. Edited by Mandell GL, Bennett JE, Dolin R. Philadelpia: Churchill Livingston; 2000:2259–2265.
Ahmed K, Rikitomi N, Ichinose A, Matsumoto K: Possible presence of a capsule in Branhamella catarrhalis. Microbiol Immunol 1999, 35:361–366.
McMichael JC: Vaccines for Moraxella catarrhalis. Vaccine 2000, 19 (Suppl l):S101-S107.
Aebi C, LaFontaine ER, Cope LD, et al.: Phenotypic effect of isogenic UspA1 and UspA2 mutations on Moraxella catarrhalis strain O35E. Infect Immun 1998, 66:3113–3119.
McMichael JC, Fiske MJ, Fredenburg RA, et al.: Isolation and characterization of two proteins from Moraxella catarrhalis that bear a common epitope. Infect Immun 1998, 66:4374–4381.
Masoud H, Perry MB, Richards JC: Characterization of the lipopolysaccharide of Moraxella catarrhalis. Eur J Biochem 1994, 220:209–216.
Rahman M, Holme T: Antibody response in rabbits to serotype-specific determinants in lipopolysaccharides from Moraxella catarrhalis. J Med Microbiol 1996, 44:348–354.
Henriksen SD: Moraxella, Neisseria, Branhamella and Acinetobacter. Ann Rev Microbiol 1976, 30:63–83.
Vaneechoutte M, Verschraegen G, Claeys G, et al.: Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of Moraxella catarrhalis from sputum. J Clin Microbiol 1990, 28:2674–2680.
Ejlertsen T, Thisted E, Ebbesen F, et al.: Branhamella catarrhalis children and adults. A study of prevalence, time of colonization and association with upper and lower respiratory tract infections. J Infect 1994, 29:23–31.
Faden H, Harabuchi Y, Hong JJ: Epidemiology of Moraxella catarrrhalis in children during the first two years of life: relationship to otitis media. J Infect Dis 1994, 169:1312–1317.
Klinman KL, Pye A, Murphy TF, Hill SL: Dynamics of respiratory tract colonization by Branhamella catarrhalis in bronchiectasis. Am J Respir Crit Care Med 1995, 152:1072–1078.
Murphy TF: Branhamella catarrhalis: Epidemiology, surface antigenic structure, and immune response. Microbiol Rev 1996, 60:267–279.
Boyle FM, Georghiou PR, Tilse M, McCormack JG: Branhamella (Moraxella) catarrhalis: pathogenic significance in respiratory infections. Med J Aust 1991, 154:592–596.
Murphy TF, Sethi S: Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992, 146:1067–1083.
Wright PW, Wallace RJ, Shepherd JR: A descriptive study of 42 cases of Branhamella catarrhalis pneumonia. Am J Med 1990, 88 (Suppl 5A):2–8.
Klein JO: Current issues in upper respiratory tract infections in infants and children: rational for antibacterial therapy. Pediatr Infect Dis J 1994, 13:5–9.
Richards SJ, Greening AP, Enright MC, et al.: Outbreak of Moraxella catarrhalis in a respiratory unit. Thorax 1993, 48:91–92.
Ikram RB, Nixon M, Aitken J, Wells E: A prospective study of isolation of Moraxella catarrhalis in a hospital during the winter months. J Hosp Infect 1993, 25:7–14.
Hoi-Dang AB, Brive-Le Bouguenec C, Barthelemy M, et al.: Novel beta-lactamase from Branhamella catarrhalis. Ann Microbiol (Paris) 1978, 129B:397–406.
Thornsberry C, Sahm DF, Kelly LJ, et al.: Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis 2002, 34(Suppl 1):S4-S16.
Fung CP, Yeo SF, Livermore DM: Extraction beta-lactamase from Moraxella catarrhalis. J Antimicrob Chemother 1994, 34:183–184.
Wallace RJ Jr, Nash DR, Steingrube VA: Antibiotic susceptibilities and drug resistance in Moraxella catarrhalis. Am J Med 1990, 88:46S-50S.
Doern GV: Resistance among problem respiratory pathogens in pediatrics. Pediatr Infect Dis J 1995, 14:420–423.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Naheed, N., Alam, M. & Lutwick, L.I. Gram-negative diplococcal respiratory infections. Curr Infect Dis Rep 5, 238–245 (2003). https://doi.org/10.1007/s11908-003-0079-6
Issue Date:
DOI: https://doi.org/10.1007/s11908-003-0079-6